Vertex Pharmaceuticals Stock (NASDAQ:VRTX)


ForecastRevenueOwnershipFinancialsChartTranscripts

Previous Close

$453.55

52W Range

$341.90 - $510.64

50D Avg

$477.47

200D Avg

$444.53

Market Cap

$117.52B

Avg Vol (3M)

$1.08M

Beta

0.40

Div Yield

-

VRTX Company Profile


Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAFTA for the treatment of patients with CF 6 years of age or older who have at least one F508del mutation. Its pipeline includes VX-864 for the treatment of AAT deficiency, which is in Phase 2 clinical trial; VX-147 for the treatment of APOL1-mediated focal segmental glomerulosclerosis, or FSGS, and other serious kidney diseases which is in Phase 2 clinical trial; VX- 880, treatment for Type 1 Diabetes which is in Phase 1/2 clinical trial; VX-548, a NaV1.8 inhibitor for treatments of acute, neuropathic, musculoskeletal pain which is in Phase 2 clinical trial; and CTX001 for the treatment severe SCD and TDT which is in Phase 3 clinical trial. The company sells its products primarily to specialty pharmacy and specialty distributors in the United States, as well as specialty distributors and retail chains, and hospitals and clinics internationally. It has collaborations with Affinia Therapeutics, Inc.; Arbor Biotechnologies, Inc.; CRISPR Therapeutics AG.; Kymera Therapeutics, Inc.; Mammoth Biosciences, Inc.; Moderna, Inc.; Obsidian Therapeutics, Inc.; and Skyhawk Therapeutics, Inc.; as well as Ribometrix, Inc.; Genomics plc; Merck KGaA; Darmstadt, Germany, and X-Chem, Inc. Vertex Pharmaceuticals Incorporated was founded in 1989 and is headquartered in Boston, Massachusetts.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

US

Employees

5,400

IPO Date

Jul 24, 1991

Website

VRTX Performance


Revenue Breakdown


Revenue Breakdown by Product/Service

Product/ServiceDec 23Dec 22Dec 21
Product$9.87B--
ORKAMBI$326.00M$510.70M$771.60M
KALYDECO$475.50M$553.20M$684.20M
TRIKAFTA/KAFTRIO$8.94B$7.69B$5.70B
SYMDEKO/SYMKEVI$123.00M$180.00M$420.40M
Collaborative and Royalty--$1.00M

Fiscal year ends in Dec 23 | Currency in USD

VRTX Financial Summary


Dec 23Dec 22Dec 21
Revenue$9.84B$8.93B$7.57B
Operating Income$3.75B$4.31B$2.78B
Net Income$3.62B$3.32B$2.34B
EBITDA$3.93B$4.35B$2.79B
Basic EPS$14.05$12.97$9.09
Diluted EPS$13.89$12.82$9.01

Fiscal year ends in Dec 23 | Currency in USD

Latest Earnings Call Transcripts


Q2 24Aug 01, 24 | 8:37 PM
Q1 24May 06, 24 | 12:00 AM
Q4 23Feb 05, 24 | 8:49 PM

Peer Comparison


TickerCompany
DNAGinkgo Bioworks Holdings, Inc.
BNTXBioNTech SE
PTCTPTC Therapeutics, Inc.
CRSPCRISPR Therapeutics AG
REGNRegeneron Pharmaceuticals, Inc.
SRPTSarepta Therapeutics, Inc.
BMRNBioMarin Pharmaceutical Inc.
NTLAIntellia Therapeutics, Inc.
EDITEditas Medicine, Inc.
VERVVerve Therapeutics, Inc.
ALNYAlnylam Pharmaceuticals, Inc.
CRBUCaribou Biosciences, Inc.
VKTXViking Therapeutics, Inc.
MRNAModerna, Inc.
KRYSKrystal Biotech, Inc.
BEAMBeam Therapeutics Inc.
MDGLMadrigal Pharmaceuticals, Inc.